Plasminogen Activating Inhibitor-1 Might Predict the Efficacy of Anti-PD1 Antibody in Advanced Melanoma Patients
Plasminogen activating inhibitor-1 (PAI-1) plays crucial roles in the development of various cancers, including melanomas. Indeed, various pro-tumorigenic functions of PAI-1 in cancer progression and metastasis have been widely reported. Among them, PAI-1 is also reported as a key regulator of PD-L1...
Guardado en:
Autores principales: | Kentaro Ohuchi, Yumi Kambayashi, Takanori Hidaka, Taku Fujimura |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f2cdaabb1655498a93333cfcd2e3169c |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Single-cell RNA sequencing to characterize the response of pancreatic cancer to anti-PD-1 immunotherapy
por: Jing Zhou, et al.
Publicado: (2022) -
Clinical observation of the efficacy of PD‐1/PD‐L1 inhibitors in the treatment of patients with advanced solid tumors
por: Miao Wang, et al.
Publicado: (2021) -
Características sociodemográficas y su influencia en el uso de Tecnologías de Información en Chile
por: Canessa,Enrique, et al.
Publicado: (2011) -
EGCG Inhibits Tumor Growth in Melanoma by Targeting JAK-STAT Signaling and Its Downstream PD-L1/PD-L2-PD1 Axis in Tumors and Enhancing Cytotoxic T-Cell Responses
por: Dinoop Ravindran Menon, et al.
Publicado: (2021) -
Cost-Effectiveness of Ipilimumab Plus Anti-PD-1 Therapy Versus Ipilimumab Alone in Patients With Metastatic Melanoma Resistant to Anti-PD-(L)1 Monotherapy
por: Ye Peng, et al.
Publicado: (2021)